| Category | Candidate | Target | Indication | Preclinical | IND | Phase I | Phase II | Registration Trial | Application | Progress* and Upcoming Milestone | Partner |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Core Pipeline | MIL62 | Third-generation CD20 (ADCC-enhanced) | Primary membranous nephropathy (PMN) | NDA accepted and included in the priority review procedure | |||||||
| Follicular lymphoma(FL) | Phase III trial (recruiting) |
||||||||||
| Systemic Lupus Erythematosus（SLE） | Phase II/III trial (recruiting) | ||||||||||
| Neuromyelitis optical spectrum disorder (NMOSD) | NDA accepted and included in the priority review procedure | ||||||||||
| Primary Pipeline |  MIL116 |
APRIL | IgA | IND approved | Climb Bio, Inc. | ||||||
| MBS303/MSC303 | CD20/CD3 | B cell non-Hodgkin Lymphoma (B-NHL) | Phase I/II trial (recruiting) | ||||||||
| Immune-mediated Glomerulonephritis | IND approved | ||||||||||
| MBS314 |
GPRC5D/BCMA/CD3 | Multiple Myeloma（MM） | Phase I/II trial (recruiting) | ||||||||
| Other Pipeline | MIL86 | PCSK9 | Hyperlipidemia | Phase II trial (completed) | |||||||
| MIL93 | Claudin 18.2 (ADCC-enhanced) | Claudin 18.2-positive gastric cancer, gastroesophageal junction cancer and pancreatic cancer | Phase I/II trial (recruiting) | ||||||||
| MIL98 | LAG3 | Melanoma, late-stage lymphoma and other late-stage malignant solid tumors | Phase I trial (completed) | ||||||||
| MIL97 | CD40 | Metastatic pancreatic cancer and other solid tumors | Phase I trial (completed) | ||||||||
Core Pipeline
Primary Pipeline
Other Pipeline
Planned trial to be initiated
Collaborative pipeline
